ΔΕΛΤΙΟ ΤΥΠΟΥ ΔΕΛΤΙΟ ΤΥΠΟΥ ΔΕΛΤΙΟ ΤΥΠΟΥ

H1 2026 Financial Results

Paiania, 17 September 2026 – The Lavipharm Group, during H1 2026, reported a significant increase in consolidated sales prior to clawback and rebate of 24.1%, while EBITDA from continuing operations increased by 5.2%.

Specifically, consolidated sales from continuing operations amounted to €38.5 million, compared to €31.0 million in the corresponding period of 2025, recording an increase of 24.1%. In particular, sales abroad increased by 35%, sales of prescription medicines in the domestic market increased by 23%, while OTC sales increased by 3%. Consolidated sales, after the deduction of clawback and rebates, amounted to €34.4 million, compared to €26.7 million in the corresponding period of 2025, representing an increase of 28.9%. Total adjusted EBITDA stood at €7.1 million, compared to €7.7 million in H1 2025, representing a decrease of 7.7%, due to the extraordinary income of €0.9 million from the sale of Pharma Plus, which took place in H1 2025.

Consolidated earnings after taxes amounted to €2.4 million, compared to €2.6 million in H1 2025. This decrease is also attributable to the income from the sale of Pharma Plus recognized in H1 2025. It is worth noting that, excluding this specific income, net earnings from continuing operations increased by 41.3% compared to H1 2025.

The Group's net debt, as at 30/6/2026, stood at €37.7 million, representing an increase compared to 31/12/2025 due to the bank financing of the DUROGESIC® acquisition.

Mr. Vassilis Baloumis, Chief Financial Officer of Lavipharm, stated: "The Group's upward trajectory will continue at a faster pace in H2 2026. Sales for the period are expected to be significantly higher than those of the first half, both in the domestic market and abroad, where the pace of order fulfillment will accelerate particularly towards the end of the year. It is worth noting that this estimate does not include DUROGESIC®, whose commercial distribution is expected to begin in early October, as the licensing procedures have already been completed in the countries of greatest commercial interest. Finally, it should be noted that the H1 figures include approximately €300 thousand in payroll-related expenses incurred in preparation for the commercialization of this specific product."

###

For further information:

Investor Relations
Vassilis Baloumis
Tel. +30 210 6691 121
ir@lavipharm.com

Corporate Communications
Vivienne Thomas

Tel. +30 210 6691 404
vthomas@lavipharm.com